［1］Lu HY，Wang XJ，Mao WM.Targeted therapies in small cell lung cancer.Oncol Lett，2013，5（1）：3-11

［2］Rudin CM，Durinck S，Stawiski EW，et al.Comprehensive genomic analysis identifies SOX2as a frequently amplified gene in small-cell lung cancer.Nat Genet，2012，44（10）：1111-1116

［3］Hall RD，Gray JE，Chiappori AA.Beyond the standard of care：a review of novel immunotherapy trials for the treatment of lung cancer.Cancer Control，2013，20（1）：22-31

［4］Pleasance ED，Stephens PJ，O′Meara S，et al.A small-cell lung cancer genome with complex signatures of tobacco exposure.Nature，2010，463（7278）：184-190

［5］Cao J，Song Y，Bi N，et al.DNA Methylation-Mediated Repression of miR-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer.Cancer Res，2013，73（11）：3326-3335

［6］Doll R，Pike MC.Trends in mortality among British doctors in relation to their smoking habits.J R Coll Physicians Lond，1972，6（2）：216-222

［7］Chen J，Qi Y，Wampfler JA，et al.Effect of cigarette smoking on quality of life in small cell lung cancer patients.Eur J Cancer，2012，48（11）：1593-1601

［8］Kalemkerian GP，Akerley W，Bogner P，et al.Small cell lung cancer.J Natl Compr Canc Netw，2013，11 （1）：78-98

［9］Boffetta P.A review of cancer risk in the trucking industry，with emphasis on exposure to diesel exhaust. G Ital Med Lav Ergon，2012，34（3）：365-370

［10］Arsenic，metals，fibres，and dusts.IARC Monogr Eval Carcinog Risks Hum，2012，100（Pt C）：11-465

［11］Personal habits and indoor combustions.Volume 100E.A review of human carcinogens.IARC Monogr Eval Carcinog Risks Hum，2012，100（Pt E）：1-538

［12］Chemical agents and related occupations.IARC Monogr Eval Carcinog Risks Hum，2012，100（Pt F）：9-562

［13］Radiation.IARC Monogr Eval Carcinog Risks Hum，2012，100（Pt D）：7-303

［14］Peifer M，Fernandez-Cuesta L，Sos ML，et al.Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.Nat Genet，2012，44（10）：1104-1110

［15］Joshi M，Ayoola A，Belani CP.Small-cell lung cancer：an update on targeted therapies.Adv Exp Med Biol，2013，779：385-404

［16］Stovold R，Blackhall F，Meredith S，et al.Biomarkers for small cell lung cancer：neuroendocrine，epithelial and circulating tumour cells.Lung Cancer，2012，76（3）：263-268

［17］Park KS，Liang MC，Raiser DM，et al.Characterization of the cell of origin for small cell lung cancer.Cell Cycle，2011，10（16）：2806-2815

［18］Sutherland KD，Proost N，Brouns I，et al.Cell of origin of small cell lung cancer：inactivation of Trp53 and Rb1in distinct cell types of adult mouse lung.Cancer Cell，2011，19（6）：754-764

［19］Hassan MI，Naiyer A，Ahmad F.Fragile histidine triad protein：structure，function，and its association with tumorogenesis.J Cancer Res Clin Oncol，2010，136（3）：333-350

［20］Sozzi G，Veronese ML，Negrini M，et al.The FHIT gene 3p14.2is abnormal in lung cancer.Cell，1996，85（1）：17-26

［21］Sard L，Accornero P，Tornielli S，et al.The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control.Proc Natl Acad Sci U S A，1999，96（15）：8489-8492

［22］Dammann R，Takahashi T，Pfeifer GP.The CpG island of the novel tumor suppressor gene RASSF1Ais intensely methylated in primary small cell lung carcinomas.Oncogene，2001，20（27）：3563-3567

［23］Pelosi G，Fumagalli C，Trubia M，et al.Dual role of RASSF1as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung.Anticancer Res，2010，30（10）：4269-4281

［24］Ji L，Nishizaki M，Gao B，et al.Expression of several genes in the human chromosome 3p21.3homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res，2002，62（9）：2715-2720

［25］Kondo M，Ji L，Kamibayashi C，et al.Overexpression of candidate tumor suppressor gene FUS1isolated from the 3p21.3homozygous deletion region leads to G1arrest and growth inhibition of lung cancer cells.Oncogene，2001，20（43）：6258-6262

［26］Du L，Schageman JJ，Subauste MC，et al.miR-93，miR-98，and miR-197regulate expression of tumor suppressor gene FUS1.Mol Cancer Res，2009，7（8）：1234-1243

［27］Lu C，Stewart DJ，Lee JJ，et al.Phase I clinical trial of systemically administered TUSC2（FUS1） _-nanoparticles mediating functional gene transfer in humans.PLoS One，2012，7（4）：e34833

［28］Virmani AK，Rathi A，Zochbauer-Muller S，et al.Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas.J Natl Cancer Inst，2000，92（16）：1303-1307

［29］Iwasaki Y，Sunaga N，Tomizawa Y，et al.Epigenetic inactivation of the thyroid hormone receptor beta1 gene at 3p24.2in lung cancer.Ann Surg Oncol，2010，17（8）：2222-2228

［30］Fong KM，Sekido Y，Minna JD.Molecular pathogenesis of lung cancer.J Thorac Cardiovasc Surg，1999，118（6）：1136-1152

［31］D′Angelo SP，Pietanza MC.The molecular pathogenesis of small cell lung cancer.Cancer Biol Ther，2010，10（1）：1-10

［32］Chiappori AA，Soliman H，Janssen WE，et al.INGN-225：a dendritic cell-based p53vaccine（Ad.p53-DC）in small cell lung cancer：observed association between immune response and enhanced chemotherapy effect.Expert Opin Biol Ther，2010，10（6）：983-991

［33］Pietanza MC，Ladanyi M.Bringing the genomic landscape of small-cell lung cancer into focus.Nat Genet，2012，44（10）：1074-1075

［34］Schaffer BE，Park KS，Yiu G，et al.Loss of p130accelerates tumor development in a mouse model for human small-cell lung carcinoma.Cancer Res，2010，70（10）：3877-3883

［35］Agathanggelou A，Cooper WN，Latif F.Role of the Ras-association domain family 1tumor suppressor gene in human cancers.Cancer Res，2005，65（9）：3497-3508

［36］Kim SK，Su LK，Oh Y，et al.Alterations of PTEN/MMAC1，a candidate tumor suppressor gene，and its homologue，PTH2，in small cell lung cancer cell lines.Oncogene，1998，16（1）：89-93

［37］Yokomizo A，Tindall DJ，Drabkin H，et al.PTEN/MMAC1mutations identified in small cell，but not in non-small cell lung cancers.Oncogene，1998，17（4）：475-479

［38］Li D，Zhang Y，Xie Y，et al.Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer.Cancer Gene Ther，2013，20（4）：251-259

［39］Hook KE，Garza SJ，Lira ME，et al.An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.Mol Cancer Ther，2012，11（3）：710-719

［40］Ganti AK，West WW，Zhen W.Current concepts in the management of small cell lung cancer.Indian J Med Res，2013，137（6）：1043-1051

［41］Faber AC，Ebi H，Costa C，et al.Apoptosis in targeted therapy responses：the role of BIM.Adv Pharmacol，2012，65：519-542

［42］Gansner JM，Rosas IO.Telomeres in lung disease.Transl Res，2013

［43］Sarvesvaran J，Going JJ，Milroy R，et al.Is small cell lung cancer the perfect target for anti-telomerase treatment？Carcinogenesis，1999，20（8）：1649-1651

［44］Ruden M，Puri N.Novel anticancer therapeutics targeting telomerase.Cancer Treat Rev，2013，39（5）：444-456

［45］Williams SC.No end in sight for telomerase-targeted cancer drugs.Nat Med，2013，19（1）：6

［46］D′Arcangelo M，D′Incecco A，Cappuzzo F.Rare mutations in non-small-cell lung cancer.Future Oncol，2013，9（5）：699-711

［47］Wojtalla A，Arcaro A.Targeting phosphoinositide 3-kinase signalling in lung cancer.Crit Rev Oncol Hematol，2011，80（2）：278-290

［48］Papadimitrakopoulou V.Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.J Thorac Oncol，2012，7（8）：1315-1326

［49］Engelman JA.Targeting PI3Ksignalling in cancer：opportunities，challenges and limitations.Nat Rev Cancer，2009，9（8）：550-562

［50］Wojtalla A，Fischer B，Kotelevets N，et al.Targeting the phosphoinositide 3-kinase p110-alpha isoform impairs cell proliferation，survival，and tumor growth in small cell lung cancer.Clin Cancer Res，2013，19 （1）：96-105

［51］Marinov M，Ziogas A，Pardo OE，et al.AKT/mTOR pathway activation and BCL-2family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.Clin Cancer Res，2009，15 （4）：1277-1287

［52］Fischer B，Marinov M，Arcaro A.Targeting receptor tyrosine kinase signalling in small cell lung cancer （SCLC）：what have we learned so far？Cancer Treat Rev，2007，33（4）：391-406

［53］Pandya KJ，Dahlberg S，Hidalgo M，et al.A randomized，phaseⅡtrial of two dose levels of temsirolimus（CCI-779）in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy：a trial of the Eastern Cooperative Oncology Group（E1500）.J Thorac Oncol，2007，2（11）：1036-1041

［54］Tarhini A，Kotsakis A，Gooding W，et al.PhaseⅡstudy of everolimus（RAD001）in previously treated small cell lung cancer.Clin Cancer Res，2010，16（23）：5900-5907

［55］Massacesi C，di Tomaso E，Fretault N，et al.Challenges in the clinical development of PI3Kinhibitors.Ann N Y Acad Sci，2013，1280：19-23

［56］Watkins DN，Berman DM，Baylin SB.Hedgehog signaling：progenitor phenotype in small-cell lung cancer.Cell Cycle，2003，2（3）：196-198

［57］Nusslein-Volhard C，Wieschaus E.Mutations affecting segment number and polarity in Drosophila.Nature，1980，287（5785）：795-801

［58］Rubin LL，de Sauvage FJ.Targeting the Hedgehog pathway in cancer.Nat Rev Drug Discov，2006，5 （12）：1026-1033

［59］Varjosalo M，Taipale J.Hedgehog：functions and mechanisms.Genes Dev，2008，22（18）：2454-2472

［60］Watkins DN，Berman DM，Burkholder SG，et al.Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer.Nature，2003，422（6929）：313-317

［61］Vestergaard J，Pedersen MW，Pedersen N，et al.Hedgehog signaling in small-cell lung cancer：frequent in vivo but a rare event in vitro.Lung Cancer，2006，52（3）：281-290

［62］Zarogoulidis P，Zarampouka K，Huang H，et al.Hedgehog signaling pathway：the must，the maybe and the unknown.J Thorac Dis，2013，5（2）：195-197

［63］Potzsch J，Schramm T.Role of environmental factors in cancer etiology.Arch Geschwulstforsch，1990，60（3）：235-239

［64］Ito T，Udaka N，Yazawa T，et al.Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium.Development，2000，127（18）：3913-3921

［65］Alamgeer M，Peacock CD，Matsui W，et al.Cancer stem cells in lung cancer：Evidence and controversies.Respirology，2013，18（5）：757-764

［66］Bridges E，Oon CE，Harris A.Notch regulation of tumor angiogenesis.Future Oncol，2011，7（4）：569-588

［67］Osanyingbemi-Obidi J，Dobromilskaya I，Illei PB，et al.Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo.Mol Cancer Res，2011，9（12）：1746-1754

［68］Ball DW，Azzoli CG，Baylin SB，et al.Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors.Proc Natl Acad Sci U S A，1993，90（12）：5648-5652

［69］Phng LK，Gerhardt H.Angiogenesis：a team effort coordinated by notch.Dev Cell，2009，16（2）：196-208

［70］Paripati A，Kingsley C，Weiss GJ.Pathway targets to explore in the treatment of small cell and large cell lung cancers.J Thorac Oncol，2009，4（11）：1313-1321

［71］Galli C，Piemontese M，Lumetti S，et al.The importance of WNT pathways for bone metabolism and their regulation by implant topography.Eur Cell Mater，2012，24：46-59

［72］Niehrs C.The complex world of WNT receptor signalling.Nat Rev Mol Cell Biol，2012，13（12）：767-779

［73］Anastas JN，Moon RT.WNT signalling pathways as therapeutic targets in cancer.Nat Rev Cancer，2013，13（1）：11-26

［74］Polakis P.Drugging Wnt signalling in cancer.EMBO J，2012，31（12）：2737-2746

［75］Ding XY，Ding J，Wu K，et al.Cross-talk between endothelial cells and tumor via delta-like ligand 4/ Notch/PTEN signaling inhibits lung cancer growth.Oncogene，2012，31（23）：2899-2906

［76］Podar K，Anderson KC.Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.Curr Cancer Drug Targets，2011，11（9）：1005-1024

［77］Katoh M，Nakagama H.FGF Receptors：Cancer Biology and Therapeutics.Med Res Rev，2013

［78］Pardo OE，Latigo J，Jeffery RE，et al.The fibroblast growth factor receptor inhibitor PD173074blocks small cell lung cancer growth in vitro and in vivo.Cancer Res，2009，69（22）：8645-8651

［79］Lund EL，Thorsen C，Pedersen MW，et al.Relationship between vessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in small cell lung cancer in vivo and in vitro.Clin Cancer Res，2000，6（11）：4287-4291

［80］Pardo OE，Arcaro A，Salerno G，et al.Fibroblast growth factor-2induces translational regulation of Bcl-XL and Bcl-2via a MEK-dependent pathway：correlation with resistance to etoposide-induced apoptosis.J Biol Chem，2002，277（14）：12040-12046

［81］Pardo OE，Wellbrock C，Khanzada UK，et al.FGF-2protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon，B-Raf and S6K2.EMBO J，2006，25（13）：3078-3088

［82］Young RJ，Tin AW，Brown NJ，et al.Analysis of circulating angiogenic biomarkers from patients in two phaseⅢtrials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.Br J Cancer，2012，106（6）：1153-1159

［83］Andre F，Bachelot T，Campone M，et al.Targeting FGFR with Dovitinib（TKI258）：Preclinical and Clinical Data in Breast Cancer.Clin Cancer Res，2013，19（13）：3693-3702

［84］Jeffers M，Rong S，Vande Woude GF.Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis.J Mol Med（Berl），1996，74（9）：505-513

［85］Surati M，Patel P，Peterson A，et al.Role of MetMAb（OA-5D5）in c-MET active lung malignancies.Expert Opin Biol Ther，2011，11（12）：1655-1662

［86］Lefebvre J，Ancot F，Leroy C，et al.Met degradation：more than one stone to shoot a receptor down.FASEB J，2012，26（4）：1387-1399

［87］Song J，Li M，Tretiakova M，et al.Expression patterns of PAX5，c-Met，and paxillin in neuroendocrine tumors of the lung.Arch Pathol Lab Med，2010，134（11）：1702-1705

［88］Birchmeier C，Birchmeier W，Gherardi E，et al.Met，metastasis，motility and more.Nat Rev Mol Cell Biol，2003，4（12）：915-925

［89］Arriola E，Canadas I，Arumi-Uria M，et al.MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines.Br J Cancer，2011，105（6）：814-823

［90］Lee RJ，Smith MR.Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer.Cancer J，2013，19（1）：90-98

［91］Koudelakova V，Kneblova M，Trojanec R，et al.Non-small cell lung cancer-genetic predictors.Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub，2013，157（2）：125-136

［92］Ferte C，Loriot Y，Clemenson C，et al.IGF-1RTargeting Increases the Antitumor Effects of DNA-Damaging Agents in SCLC Model：An Opportunity to Increase the Efficacy of Standard Therapy.Mol Cancer Ther，2013，12（7）：1213-1222

［93］Gately K，Collins I，Forde L，et al.A role for IGF-1R-targeted therapies in small-cell lung cancer？Clin Lung Cancer，2011，12（1）：38-42

［94］Badzio A，Wynes MW，Dziadziuszko R，et al.Increased insulin-like growth factor 1receptor protein expression and gene copy number in small cell lung cancer.J Thorac Oncol，2010，5（12）：1905-1911

［95］Weickhardt A，Doebele R，Oton A，et al.A phaseⅠ/Ⅱstudy of erlotinib in combination with the antiinsulin-like growth factor-1receptor monoclonal antibody IMC-A12（cixutumumab）in patients with advanced non-small cell lung cancer.J Thorac Oncol，2012，7（2）：419-426

［96］Yee D.Insulin-like growth factor receptor inhibitors：baby or the bathwater？J Natl Cancer Inst，2012，104（13）：975-981

［97］Chen HX，Sharon E.IGF-1Ras an anti-cancer target--trials and tribulations.Chin J Cancer，2013，32 （5）：242-252

［98］Scagliotti GV，Novello S.The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors.Cancer Treat Rev，2012，38（4）：292-302

［99］Zinn RL，Gardner EE，Marchionni L，et al.ERK Phosphorylation Is Predictive of Resistance to IGF-1R Inhibition in Small Cell Lung Cancer.Mol Cancer Ther，2013，12（6）：1131-1139

［100］Boldrini L，Ursino S，Gisfredi S，et al.Expression and mutational status of c-kit in small-cell lung cancer：prognostic relevance.Clin Cancer Res，2004，10（12Pt 1）：4101-4108

［101］Sattler M，Salgia R.Targeting c-Kit mutations：basic science to novel therapies.Leuk Res，2004，28 Suppl 1：S11-20

［102］Johnson FM，Krug LM，Tran HT，et al.PhaseⅠstudies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.Cancer，2006，106（2）：366-374

［103］Lu HY，Zhang G，Cheng QY，et al.Expression and mutation of the c-kit gene and correlation with prognosis of small cell lung cancer.Oncol Lett，2012，4（1）：89-93

［104］Yoshida C，Tsuji AB，Sudo H，et al.Therapeutic efficacy of c-kit-targeted radioimmunotherapy using 90Y-labeled anti-c-kit antibodies in a mouse model of small cell lung cancer.PLoS One，2013，8 （3）：e59248

［105］Horn L，Dahlberg SE，Sandler AB，et al.PhaseⅡstudy of cisplatin plus etoposide and bevacizumab for previously untreated，extensive-stage small-cell lung cancer：Eastern Cooperative Oncology Group Study E3501.J Clin Oncol，2009，27（35）：6006-6011

［106］Spigel DR，Greco FA，Zubkus JD，et al.PhaseⅡtrial of irinotecan，carboplatin，and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.J Thorac Oncol，2009，4（12）：1555-1560

［107］Ready NE，Dudek AZ，Pang HH，et al.Cisplatin，irinotecan，and bevacizumab for untreated extensivestage small-cell lung cancer：CALGB 30306，aphaseⅡstudy.J Clin Oncol，2011，29（33）：4436-4441

［108］Spigel DR，Townley PM，Waterhouse DM，et al.Randomized phaseⅡstudy of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer：results from the SALUTE trial.J Clin Oncol，2011，29（16）：2215-2222

［109］Arnold AM，Seymour L，Smylie M，et al.PhaseⅡstudy of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy：National Cancer Institute of Canada Clinical Trials Group Study BR.20.J Clin Oncol，2007，25 （27）：4278-4284

［110］Ramalingam SS，Belani CP，Mack PC，et al.PhaseⅡstudy of Cediranib（AZD 2171），an inhibitor of the vascular endothelial growth factor receptor，for second-line therapy of small cell lung cancer （National Cancer Institute#7097）.J Thorac Oncol，2010，5（8）：1279-1284

［111］Gitlitz BJ，Moon J，Glisson BS，et al.Sorafenib in platinum-treated patients with extensive stage small cell lung cancer：a Southwest Oncology Group（SWOG 0435）phaseⅡtrial.J Thorac Oncol，2010，5 （11）：1835-1840

［112］Spigel DR，Greco FA，Rubin MS，et al.PhaseⅡstudy of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.Lung Cancer，2012，77（2）：359-364

［113］Han JY，Kim HY，Lim KY，et al.A phaseⅡstudy of sunitinib in patients with relapsed or refractory small cell lung cancer.Lung Cancer，2013，79（2）：137-142

［114］Lee SM，James L，Buchler T，et al.PhaseⅡtrial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer.Lung Cancer，2008，59（3）：364-368

［115］Langer CJ，Mok T，Postmus PE.Targeted agents in the third _-/fourth-line treatment of patients with advanced（stageⅢ/Ⅳ）non-small cell lung cancer（NSCLC）.Cancer Treat Rev，2013，39（3）：252-260

［116］Pillai RN，Ramalingam SS.Hsp90inhibitors.J Thorac Oncol，2012，7（16Suppl 5）：S407-408

［117］Garcia-Carbonero R，Carnero A，Paz-Ares L.Inhibition of HSP90molecular chaperones：moving into the clinic.Lancet Oncol，2013，14（9）：e358-369

［118］Rodina A，Vilenchik M，Moulick K，et al.Selective compounds define Hsp90as a major inhibitor of apoptosis in small-cell lung cancer.Nat Chem Biol，2007，3（8）：498-507

［119］Jhaveri K，Taldone T，Modi S，et al.Advances in the clinical development of heat shock protein 90 （Hsp90）inhibitors in cancers.Biochim Biophys Acta，2012，1823（3）：742-755

［120］Connor JP，Cristea MC，Lewis NL，et al.A phase 1bstudy of humanized KS-interleukin-2（huKS-IL2）immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors. BMC Cancer，2013，13：20